Try our mobile app

AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis

Published: 2020-08-25 12:45:00 ET
<<<  go to ABBV company page

- RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1]

- In a pivotal Phase 2/3 study, twice as many patients receiving RINVOQ achieved the primary endpoint of ASAS 40 response at week 14 compared to placebo (p